- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
CNBC reported Areva (EPA:AREVA) saw revenues decline 2.6% in 2011 after a uranium mining disaster, change in leadership and global uranium price drop.
CNBC reported Areva (EPA:AREVA) saw revenues decline 2.6% in 2011 after a uranium mining disaster, change in leadership and global uranium price drop.
As quoted in the market news:
The company’s new chief executive, Luc Oursel, unveiled a turnround plan at the end of last year that included the suspension of some projects, a partial hiring freeze in France and massive layoffs in Germany, which has decided to shut down all of its nuclear plants by 2022. But even with those measures, Oursel has warned that Areva will post an operating loss of between euro1.4 billion and euro1.6 billion (between $1.8 billion and $2.1 billion) for 2011. The company reports its profits March 2.
Click here to read the full CNBC report.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.